Rocket One Inc.

We are a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. We are developing three primary assets: HT-001, a topical formulation for treating side effects from cancer drugs; HT-KIT, a treatment for mast-cell derived cancers and anaphylaxis; and HT-ALZ, a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases. Additionally, we have assets under development for atopic dermatitis (BioLexa), asthma and allergies (HT-004), and obesity and related conditions (HT-VA). Our primary development focus is HT-001. On February 1, 2020, we licensed patent rights from The George Washington University for HT-001. We intend to seek approval for HT-001 to treat dermatological side effects from epidermal growth factor receptor (EGFR) inhibitors and potentially other cancer drugs. HT-001 is a topical formulation designed to treat rash and skin disorders associated with initial and repeat courses of tyrosine kinase EGFR inhibitor therapy. EGFR inhibitors are used for cancers with EGFR up-regulation, such as non-small cell lung cancer, pancreatic cancer, breast cancer, and colon cancer, but often cause dose-limiting skin toxicities. HT-001 aims to treat these EGFR-induced skin disorders to improve patient outcomes from EGFR therapy. In November 2022, we submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for HT-001 as a concomitant therapy with EGFR inhibitors for a Phase 2a clinical trial in humans. We received FDA approval to proceed with this clinical study on December 28, 2022.